Company / Free Cash Flow
4D Molecular Therapeutics, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$138.4M
FY2025
5-year range
-$138.4M / -$51.9M
FY2021-FY2025
Trend
-76.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$98M to -$138M over the past 2 years.
Based on SEC 10-K filings.
-$138M in FY2025.
Declined from -$98M to -$138M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 76.1% year-over-year.
- Peak free cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$138.4M | -76.1% |
| FY2024 | -$78.6M | +20.0% |
| FY2023 | -$98.2M | -25.5% |
| FY2022 | -$78.2M | -50.7% |
| FY2021 | -$51.9M | -30.1% |
| FY2020 | -$39.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026